The in vitro activities of carumonam and eight comparative antimicrobial agents were studied. MICs of carumonam were o0.5 ,ug/ml for 91% of members of the family Enterobacteriaceae and <16 ,ug/ml for 88% of nonfermenters; gram-positive cocci and anaerobic bacteria were resistant. Combinations of carumonam with piperacillin, nafcillin, or clindamycin were usually indifferent, although synergy between carumonam and piperacillin was observed with 20 (13%) of 155 strains.
. Carumonam is highly active against members of the family Enterobacteriaceae, moderately active against Pseudomohas aeruginosa, and inactive against gram-positive cocci (2, 4) . In this study, we compared the in vitro activity of carumonam with the activities of aztreonam, cefotaxime, ceftazidime, piperacillin, tobramycin, amikacin, nafcillin, and clindamycin against a variety of aerobic and anaerobic pathogens. Because the monobactams, like the aminoglycosides (1), have little useful activity against gram-positive cocci and anaerobic bacteria, we also compared the activities of carumonam and tobramycin, each in combination with piperacillin, nafcillin, or clindamycin, with a representative sample of the study organisms.
The organisms studied included 420 bacterial strains recently isolated from patients at The Ohio State University Hospital; 53% were isolated from blood cultures. For combination testing, 155 strains were selected to include 122 strains with carumonam MICs of -1 ,ug/ml and 103 strains with tobramycin MICs of .1 p,g/ml. clindamycin were tested. Plates were stored at -70°C until used.
MICs for aerobic bacteria were determined by a standardized microdilution method (3) in 0.1-ml volumes of cationsupplemented Mueller-Hinton broth (Difco Laboratories, Detroit, Mich.). MICs for anaerobic bacteria were determined in Schaedler broth (BBL Microbiology Systems, Cockeysville, Md.) supplemented with 1% heat-inactivated horse serum and 5 ,ug of vitamin K1 per ml (1) . Microdilution plates were inoculated with disposable inoculators (Dynatech) so that the final inoculum was approximately 5 x 105 CFU/ml. For combination testing, synergy was considered present if the MICs of both drugs in a pair were two or more dilution steps lower in combination than singly. Antagonism was considered to be present if the MICs of both drugs in a pair were two or more dilution steps higher in combination than singly. All other results were considered to be indifferent or indeterminate.
The MICs of the nine antibiotics for the 270 members of the family Enterobacteriaceae and 85 nonfermenters are shown in Table 1 . Most Enterobacteriaceae were susceptible to the monobactams, cephalosporins, and aminoglycosides tested, but only amikacin inhibited all strains in concentrations of .8 ,ug/ml. Piperacillin had variable activity, and clindamycin and nafcillin were inactive against these organisms. Carumonam inhibited 91% of Enterobacteriaceae in concentrations of c0.5 ,ug/ml, 96% in concentrations of .8 pug/ml, and 100% in concentrations of c64 ,ug/ml. The results of combination testing indicated that all six drug combinations were indifferent against most study strains. Synergy was most frequently observed with carumonam-piperacillin (13% of strains) and tobramycinpiperacillin (10% of strains). Antagonism was rarely observed.
We conclude that carumonam has a broad spectrum of activity against members of the family Enterobacteriaceae and modest activity against nonfermenters. It has little or no activity against gram-positive cocci or anaerobic bacteria, and it is likely that it will frequently be used in combination with drugs active against those organisms. Combinations of carumonam with piperacillin, nafcillin, or clindamycin are usually indifferent; the percentages of strains susceptible to combinations reflect the combined spectra of the individual drugs.
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